EMD 0.00% 5.1¢ emyria limited

Also Ben Sessa got a mention - Ran the first clinical study in...

  1. 738 Posts.
    lightbulb Created with Sketch. 233
    Also Ben Sessa got a mention - Ran the first clinical study in Australia and has been working with psychedelics for 15 years

    He is on our clinical advisory board
    I know were in good hands with the clinical team

    The only thing I am worried about is what protection do we have for the MDMA analogues,
    "VANCOUVER, BC, Feb 23, 2023 /GlobeNewswire/ PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities(NCEs). The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021.This PCT application disclosed novel compositions of MDMA and analogs thereof, which may be used to alleviate the known side effects of MDMA while retaining its efficacy."

    Keep in mind Dr Piggott has been working with these MDMA analogues for over 10 years, so where do we stand from a patent protection point of view?
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
(20min delay)
Last
5.1¢
Change
0.000(0.00%)
Mkt cap ! $18.69M
Open High Low Value Volume
4.9¢ 5.1¢ 4.9¢ $6.821K 136.4K

Buyers (Bids)

No. Vol. Price($)
2 50000 4.9¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 129118 2
View Market Depth
Last trade - 16.10pm 30/04/2024 (20 minute delay) ?
Last
5.0¢
  Change
0.000 ( 2.04 %)
Open High Low Volume
5.0¢ 5.0¢ 5.0¢ 34155
Last updated 15.59pm 30/04/2024 ?
EMD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.